The U.S. FDA has approved Sage Therapeutics' Zulresso, the first drug approved by the agency specifically to treat postpartum depression.
The intravenous injection has been approved with a Risk Evaluation and Mitigation Strategy (REMS) and is only available to patients through a restricted distribution program at certified health care facilities.
Zulresso is administered as a continuous IV infusion over a total of 60 hours. Sage said it will cost $7,450 per vial, or $34,000 for a patient’s average course of therapy -- before any discounts.
Sage is also developing a pill formulation of the drug.
Read the FDA release
Read about Sage's trial results
